Patents by Inventor Michael Kell
Michael Kell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6136801Abstract: Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.Type: GrantFiled: December 24, 1998Date of Patent: October 24, 2000Assignee: U. D. Testing, Inc.Inventor: Michael Kell
-
Patent number: 6124136Abstract: A method of monitoring compliance of a patient that has been placed on a methadone maintenance program by determining plasma methadone concentration from urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration, pH, and specific gravity are measured. The plasma methadone concentration is calculated as a function of urine methadone concentration, specific gravity, and pH. The calculated plasma methadone concentration is compared with an expected value for the maintenance program prescribed.Type: GrantFiled: November 2, 1993Date of Patent: September 26, 2000Assignee: U. D. Testing, Inc.Inventor: Michael Kell
-
Patent number: 5955370Abstract: A test method for determining adulteration by diuresis or the addition of a diuretic, which uses creatinine and specific gravity measurements to determine a normalized creatinine value for comparison with expected normalized creatinine values for the substantially diuretic-free population.Type: GrantFiled: July 7, 1997Date of Patent: September 21, 1999Assignee: U.D. Testing, Inc.Inventor: Michael Kell
-
Patent number: 5908788Abstract: A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance. Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication.Type: GrantFiled: August 19, 1996Date of Patent: June 1, 1999Assignee: U.D. Testing, Inc.Inventor: Michael Kell
-
Patent number: 5788623Abstract: This invention relates to the treatment of contaminated materials including soils and solids to reduce its permeability, and in particular to chemical treatment of waste or solids containing high levels of heavy metals such as lead, by treating the waste or solid with a single additive or combination of additives including calcium carbonate; reactive magnesium carbonate; reactive calcium magnesium carbonate; magnesium oxide; magnesium hydroxide; ammonium phosphate; diammonium phosphate; phosphoric acid; boric acid; metallic iron; polyphosphoric acid; sodium carbonate; sodium bicarbonate; calcium oxide; calcium hydroxide; sodium hydrogen phosphate; triple super phosphate (TSP); superphosphate and polyphosphoric acid.Type: GrantFiled: March 15, 1996Date of Patent: August 4, 1998Assignee: Entact, Inc.Inventors: Michael Kell Studer, Philip J. Pisani, Sherry A. Pierce
-
Patent number: 5776783Abstract: Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.Type: GrantFiled: September 17, 1996Date of Patent: July 7, 1998Assignee: Private Clinic Laboratories, Inc.Inventor: Michael Kell
-
Patent number: 5702672Abstract: An apparatus for multiple, simultaneous synthesis of compounds which consists of: a reservoir block having a plurality of wells; a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends; a holder block, having a plurality of apertures; and a manifold, which may have ports to allow introduction/maintenance of a controlled environment. The manifold top wall has apertures and a detachable plate with identical apertures. The apparatus is constructed from materials which will accommodate heating, cooling, agitation, or corrosive reagents. Gaskets are placed between the components. Rods or clamps are provided for fastening the components together. Apparatus operation involves placing the filters on the lower ends of the reaction tubes in the reservoir block wells, and the upper ends passing through the holder block apertures and into the manifold.Type: GrantFiled: October 10, 1995Date of Patent: December 30, 1997Assignee: Warner-Lambert CompanyInventors: Sheila H. H. DeWitt, Michael Kell, Michael R. Pavia, John S. Kiely, Mel C. Schroeder, Charles J. Stankovic, Steven Ware
-
Patent number: 5667696Abstract: This invention relates to the treatment of lead based paint mixtures by treating the lead based paint mixture with an additive from the group consisting of phosphoric acid, monocalcium phosphate, monoammonium phosphate and diammonium phosphate, either alone or in combination with Portland Cement.Type: GrantFiled: March 11, 1996Date of Patent: September 16, 1997Assignee: Entact, Inc.Inventors: Michael Kell Studer, Philip J. Pisani
-
Patent number: 5652146Abstract: A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine medication concentration. An unadulterated urine sample is obtained from the patient. The urine medication concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance. Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication.Type: GrantFiled: July 5, 1996Date of Patent: July 29, 1997Assignee: Private Clinic Laboratories, Inc.Inventor: Michael Kell
-
Patent number: 5602038Abstract: In a method of determining creatinine clearance for detecting and monitoring renal dysfunction, spot samples of urine and blood from a person are obtained. Specific gravity or osmolality and creatinine concentration of the urine sample are measured. Creatinine concentration of plasma of the blood sample is also measured. Creatinine clearance is calculated as a function of the measured urine specific gravity or osmolality, the measured urine creatinine concentration and the measured plasma creatinine concentration.Type: GrantFiled: January 25, 1996Date of Patent: February 11, 1997Assignee: Private Clinic Laboratories, Inc.Inventor: Michael Kell
-
Patent number: 5547878Abstract: A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication.Type: GrantFiled: May 24, 1994Date of Patent: August 20, 1996Inventor: Michael Kell
-
Patent number: 5500372Abstract: In a method of determining creatinine clearance for detecting and monitoring renal dysfunction, spot samples of urine and blood from a person are obtained. Specific gravity and creatinine concentration of the urine sample are measured. Creatinine concentration of plasma of the blood sample is also measured. Creatinine clearance is calculated as a function of the measured urine specific gravity, the measured urine creatinine concentration and the measured plasma creatinine concentration.Type: GrantFiled: July 25, 1994Date of Patent: March 19, 1996Assignee: Private Clinic Laboratories Inc.Inventor: Michael Kell